Latest Lung Cancer News | NSCLC/SCLC Treatment Information

Lung Cancers News


Lung Cancers News

Keytruda Gains Expanded Monotherapy Indication for First-Line Treatment of NSCLC

Merck announced that the Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab) as monotherapy for the first-line treatment of patients with stage III non-small cell lung cancer (NSCLC) who are not candidates for surgical resection or definitive chemoradiation, or metastatic NSCLC, and whose tumors express PD-L1 (tumor proportion score [TPS] ≥1%) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations.

A Growing Focus on Rare Cancers in Phase I Trials

This study was presented at the 2019 International Congress on Targeted Anticancer Therapies (TAT) in Paris, France, from February 25-27, 2019. Dr Jun Sato of the National Cancer Center Hospital, Japan is the lead author of this study.1 Results from a retrospective study evaluating the focus of early-phase clinical trials of investigational drug candidates in…
Next post in Lung Cancer